Lonza signs agreement to manufacture AstraZeneca’s COVID-19 treatment
BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19, a news release said. AZD7442 is currently in Phase-I clinical studies and AstraZeneca plans…